argenx NV ADR (ARGX)vsImmuCell Corporation (ICCC)
ARGX
argenx NV ADR
$865.04
-1.17%
HEALTHCARE · Cap: $54.24B
ICCC
ImmuCell Corporation
$11.00
-0.18%
HEALTHCARE · Cap: $99.79M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 17657% more annual revenue ($5.32B vs $29.93M). ARGX leads profitability with a 32.3% profit margin vs -1.8%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ICCC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$865.04
$1562.65 discount
Margin of Safety
+63.1%
Fair Value
$17.60
Current Price
$11.00
$6.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Revenue surging 28.4% year-over-year
Earnings expanding 31.3% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 182.9x book value
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -1.9% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : ICCC
The strongest argument for ICCC centers on Revenue Growth, EPS Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
ICCC carries more volatility with a beta of 0.57 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 42/100), backed by strong 32.3% margins and 59.3% revenue growth. ICCC offers better value entry with a 63.1% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?